Armed with a product patent regime and a string of large acquisitions, multinational drug companies are making a strong comeback in India.
Ten multinational companies (MNCs) — Daiichi Sankyo-controlled Ranbaxy, GlaxoSmithKline (GSK), Abbott which owns Piramal’s domestic formulation business, Pfizer, Abbott and Solvay combine, sanofi-aventis, Novartis, Merck & Co, MSD and AstraZeneca — accounted for 25.4 per cent, or Rs 11,840 crore, of the Rs 47,690-crore domestic pharmaceutical market in 2010 calendar year, according to IMS India.
Ten multinational companies (MNCs) — Daiichi Sankyo-controlled Ranbaxy, GlaxoSmithKline (GSK), Abbott which owns Piramal’s domestic formulation business, Pfizer, Abbott and Solvay combine, sanofi-aventis, Novartis, Merck & Co, MSD and AstraZeneca — accounted for 25.4 per cent, or Rs 11,840 crore, of the Rs 47,690-crore domestic pharmaceutical market in 2010 calendar year, according to IMS India.
